

This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Multiple myeloma (MM)	Ubiquitin- conjugating enzyme E2I (UBE2I; UBC9)	Studies in cell culture suggest inhibiting UBE2I could help treat MM. Levels of UBE2I were fivefold higher in blood samples from MM patients than in samples from healthy controls, and greater UBE2I expression had a nonsignificant correlation with lower survival in MM patients ($p=0.08$). Ube2I-deficient MM cell lines had less proliferative ability and higher susceptibility to radiation-induced apoptosis than wild-type MM cell lines. Ongoing studies include the development of assays to identify UBE2I inhibitors.	Unpatented; available for licensing	Driscoll, J. <i>et al. Blood</i> ; published online Nov. 30, 2009; doi:10.1182/blood-2009-03-211045 Contact: James J. Driscoll, VA Boston Healthcare System, West Roxbury, Mass. e-mail: driscollj@mail.nih.gov
<p>SciBX 3(1); doi:10.1038/scibx.2010.12 Published online Jan. 7, 2010</p>				